BioAtla to Participate in the Jefferies London Healthcare Conference
November 06, 2023 16:05 ET
|
BioAtla, Inc.
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award
October 12, 2023 07:30 ET
|
BioAtla, Inc.
SAN DIEGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023
October 10, 2023 07:30 ET
|
BioAtla, Inc.
Submitted abstract on CAB-AXL-ADC, BA3011, in non-small cell lung cancer (NSCLC) to the IASLC 2023 North America Conference on Lung Cancer; KOL event planned for December 4, 2023, following conclusion...
BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Participate in Upcoming Investor Conferences in August
August 03, 2023 16:01 ET
|
BioAtla, Inc.
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
August 01, 2023 16:01 ET
|
BioAtla, Inc.
Achieved first patient in (FPI) and continuing to enroll CAB-AXL BA3011 in a Phase 2 potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS) Submitted Food & Drug...
BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023
July 25, 2023 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index
June 26, 2023 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Participate in the Jefferies Healthcare Conference
May 31, 2023 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress
May 11, 2023 16:01 ET
|
BioAtla, Inc.
Advancing CAB-AXL BA3011 in ongoing sarcoma Phase 2 studies including a potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS); expect Leiomyosarcoma (LMS) cohort readout in...